Commercial Performance & Strategy - Invivyd's Q1 2025 net product revenue for PEMGARDA was $11.3 million[82] - HCP interactions increased by 37% from 8,608 on January 1 to 11,669 on April 30[12] - The number of accounts called on increased by 37% from 4,566 on January 1 to 6,242 on April 30[12] - Accounts ordering PEMGARDA increased by 20% from 534 on January 1 to 642 on April 30[12] - PEMGARDA is priced lower than nearly all FDA-approved monoclonal antibodies launched in the past 5 years, ranking 59 out of 63 mAb drugs based on annual pricing[24] Research & Development - VYD2311 is designed to target a highly conserved epitope on SARS-CoV-2, with >15x improved neutralization potency relative to VYD222 (PEMGARDA)[47, 51] - The in-life phase of the Phase 1 clinical trial for VYD2311 has been completed, with data read-out anticipated later in Q2 2025[50] - Invivyd is conducting discovery programs for RSV and measles, with progress updates expected by the end of 2025[5, 41, 45] Financial Status - Operating expenses decreased to $27.4 million in Q1 2025 from $32.3 million in Q4 2024[82] - The company ended Q1 2025 with approximately $48.1 million in cash and cash equivalents[82] - A $30 million loan facility was secured in April 2025[5, 82]

Core Insights - Invivyd, Inc. reported financial results for Q1 2025, highlighting a strategic shift to internalize its sales force, which initially created challenges but is now showing signs of growth and momentum [2][6][7]. Financial Results - For Q1 2025, Invivyd reported net product revenue of $11.3 million from PEMGARDA™, a decrease from $13.8 million in Q4 2024, with no revenue reported in Q1 2024 [7][15]. - The company recorded a net loss of $16.3 million for Q1 2025, an improvement from a net loss of $43.5 million in the same period of 2024, resulting in a net loss per share of $0.14 compared to $0.38 in Q1 2024 [15][28]. Cash Position and Funding - As of March 31, 2025, Invivyd had cash and cash equivalents of $48.1 million and secured a $30 million non-dilutive term loan facility to support its operations and potential growth [4][15]. Business Highlights - The company is targeting near-term profitability by the end of the first half of 2025, supported by anticipated growth in net product revenue and a reduction in operating expenses [2][7]. - PEMGARDA's uptake is increasing among healthcare providers for immunocompromised patients, aided by the internalized sales force [8]. Pipeline Developments - VYD2311 Phase 1 clinical trial data read-out is expected later in Q2 2025, with ongoing evaluations for pipeline expansion beyond SARS-CoV-2, including potential targets like respiratory syncytial virus (RSV) and measles [5][8][19]. - The FDA declined Invivyd's request to expand the EUA for PEMGARDA to treat mild-to-moderate COVID-19, but the reasoning may provide a near-term pathway for VYD2311 [8]. Regulatory and Safety Updates - Since the EUA of PEMGARDA in March 2024, no documented cases of anaphylaxis have been reported across thousands of doses administered [7][8]. - In vitro data indicate sustained neutralizing activity of PEMGARDA against dominant SARS-CoV-2 variants, which represent over 75% of circulating variants in the U.S. [8].